Physician profile
Mitspa Thomas
NPI 1477225340
$4,060.15
in general payments reported to CMS, 2019-2025
28 companies · $1,681 in 2025
The $1,681 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $730 · 2024: $1,649 · 2025: $1,681.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,976 · Education: $84.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,976.15 |
| Education | $84.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,392.70 | 2023-2025 | |
| Genzyme Corporation | $368.02 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $343.87 | 2023-2025 | Xifaxan, Trulance, Plenvu |
| Regeneron Healthcare Solutions, INC. | $343.83 | 2023-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $260.23 | 2023-2025 | Entyvio, Gattex, Eohilia |
| Madrigal Pharmaceuticals | $232.51 | 2025 | Rezdiffra |
| Phathom Pharmaceuticals, INC. | $154.88 | 2024-2025 | Voquezna |
| Janssen Biotech, INC. | $141.25 | 2025 | Tremfya |
| Gilead Sciences, INC. | $128.00 | 2025 | Livdelzi |
| E.R. Squibb & Sons, L.L.C. | $79.15 | 2023 | Zeposia |
| Ferring Pharmaceuticals INC. | $65.99 | 2024-2025 | Rebyota |
| Pfizer INC. | $56.84 | 2024-2025 | |
| Qol Medical, LLC | $51.00 | 2025 | Sucraid |
| Merck Sharp & Dohme LLC | $43.61 | 2023 | Dificid, Keytruda, Lynparza |
| Ardelyx, INC. | $41.79 | 2023-2024 | Ibsrela |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Enterra Medical, INC. | $41.39 | 2023 | |
| Braintree Laboratories, INC. | $40.21 | 2024-2025 | Suflave, Sutab |
| Novo Nordisk INC | $38.72 | 2025 | Wegovy |
| Intercept Pharmaceuticals, INC. | $36.20 | 2024-2025 | |
| Celgene Corporation | $35.83 | 2023-2024 | Zeposia |
| Celltrion USA INC. | $31.22 | 2025 | Zymfentra |
| Ipsen Biopharmaceuticals, INC | $29.94 | 2025 | Iqirvo |
| Boston Scientific Corporation | $20.66 | 2023 | Exalt Model D |
| Ironwood Pharmaceuticals, INC | $20.51 | 2024 | |
| Exact Sciences Corporation | $19.83 | 2025 | The Cologuard Plus Collection Kit |
| Evoke Pharma, INC. | $17.59 | 2025 | |
| Beone Medicines USA, INC. | $17.13 | 2025 | Tevimbra |
| Janssen Scientific Affairs, LLC | $7.25 | 2025 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitspa Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.